Navigation Links
Two Pivotal Phase III Studies for Roche's ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
Date:11/7/2007

- New data from TOWARD study highlight significant improvements in RA

symptoms achieved with the unique inhibiting action of ACTEMRA that

specifically targets interleukin-6 receptors -

NUTLEY, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Data from two pivotal multinational Phase III clinical trials demonstrating that Roche's ACTEMRA(TM) (tocilizumab) significantly improved the signs and symptoms of rheumatoid arthritis (RA) patients who failed to adequately respond to anti-rheumatic therapies -- also known as disease modifying agents (DMARDs) -- will be highlighted at the American College of Rheumatology (ACR) Annual Scientific Meeting in Boston, November 6-11.

Late-breaking data results from the TOWARD (Tocilizumab in cOmbination With traditional DMARD therapy) trial and OPTION (TOcilizumab Pivotal Trial in Methotrexate Inadequate respONders) trial will both be featured in oral presentations. Additionally, study results of the OPTION trial will be featured at an ACR press conference on Saturday, November 10 at 8:30 a.m.

"We are very encouraged by the findings of this new TOWARD data which suggest ACTEMRA plus DMARDs demonstrates significant improvement in RA symptoms compared with DMARDs alone," said Mark C. Genovese, M.D., lead study investigator of the TOWARD trial and Associate Professor of Medicine at Stanford University School of Medicine. "The data from both studies further establish the efficacy of ACTEMRA and confirm that inhibiting interleukin-6 (IL-6) receptor is a novel method of reducing RA symptoms."

In the TOWARD trial, 61% of patients in the ACTEMRA plus DMARDs arm achieved a 20% reduction in RA symptoms compared with 25% of patients in the placebo arm (p<0.0001) at 24 weeks. Within two weeks there was a measurably higher ACR20 response with ACTEMRA than the control arm. In the OPTION trial, 59% of patients in the ACTEMRA 8 mg/kg plus methotrexate arm experienced a 20% reduction in symptoms versus 27% o
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
(Date:12/17/2014)...  Beamz Interactive, Inc. (OTCQB: BZIC), a leading ... that it has signed an agreement with RSL ... innovative prosthetic, orthotic and assistive technology products and ... RSL Steeper will promote and supply the Beamz ... within UK residential care facilities through its Assistive ...
(Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today announced completion of enrollment in its first Phase ... 3-month observations confirmed the 1-month findings that were ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... 2010 Phytomedics, Inc., a transformational healthcare company ... products solely derived from plant sources, announced today ... the amount of $244,000 under the Qualifying Therapeutic ... of its lead product PMI-001 for Rheumatoid Arthritis. ...
... Nov. 9, 2010 NewCardio, Inc. (OTC Bulletin Board: ... announced today that Dr. Samuel George, NewCardio,s Senior Medical ... a blinded "testing" dataset, conducted independently by the Cardiac ... to be held on December 9, 2010, at the ...
Cached Medicine Technology:Phytomedics, Inc. Awarded QTDP Grant from U.S. Department of Health and Human Services 2NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 2NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 3NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 4
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Model Compliance Guidance , , ... Compliance Association (HCCA) announced today that it will hold ... in Scottsdale, Arizona. The HCCA,s Managed Care Compliance conference, ... to provide essential information for individuals involved with managing ...
... Calif., Dec. 4 Microchip Biotechnologies, a private company ... announced today that Ezra Van Gelder has joined its ... , Ezra Van Gelder brings ... development from the life science, medical device and semiconductor ...
... LAKE CITY, Dec. 4 The Ensign Group, Inc.,(Nasdaq: ... Ensign(TM) group of skilled nursing,rehabilitative care services and assisted ... of Infinia at Alta, an 85-bed skilled,nursing facility in ... Alta,Care & Rehabilitation Center. , ...
... can become,stressful for many families -- the pressure to find ... and co-workers, and, this,year, the added weight of a slumping ... give the gift of companionship and joy by putting a ... "Before giving a furry friend as a gift, ...
... Drs. Samuel and Elenore Bogoch of Oncolab, Inc. have found that ... proteins*, are quantitatively related to the mortality rate in human cancer ... been reported to be quantitatively related to mortality rate. , ... ...
... Wash., Dec. 4 In the midst of ... challenges in the United States,healthcare providers from across ... corporate headquarters in Redmond, Wash., for the first ... examining,ways to apply information technology (IT) innovations to ...
Cached Medicine News:Health News:HCCA Announces Managed Care Compliance Conference, February 22-24, 2009, Scottsdale, Arizona 2Health News:HCCA Announces Managed Care Compliance Conference, February 22-24, 2009, Scottsdale, Arizona 3Health News:Ezra Van Gelder Joins Microchip Biotechnologies as Executive Vice President R&D 2Health News:The Ensign Group, Inc. Acquires Utah Skilled Nursing Facility 2Health News:A Season of Responsibility for New Pet Owners 2Health News:Cancer Mortality Increases With Cancer Cell Replikin Count 2Health News:Cancer Mortality Increases With Cancer Cell Replikin Count 3Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 2Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 3Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 4
... supports are a convenient, reusable, patient-friendly ... for common orthopedic conditions/instabilities. These products ... compression and lateral to medial influence ... the skin and soft tissue structures. ...
... the medial or lateral compartment for relief ... we equipped this unique brace with our ... suitable for post-op and long-term rehab [>4weeks] ... , ,Indications: , Medial or ...
The Deluxe Knee Immobilizer provides superb lightweight immobilization following injury or surgery. It is available in a wide array of sizes for excellent comfort and fit....
... of the TROM provides the same easy ... as the full foam TROM, but is ... of use and versatility of the Cool ... following major ligament surgery, meniscal repairs, patella ...
Medicine Products: